GlassScriptPhysician profile
Robert F Gutierrez
NPI 1952388795
$3,631.72
in general payments reported to CMS, 2019-2025
32 companies · $672 in 2025
The $672 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $68.45 · 2021: $249 · 2022: $702 · 2023: $874 · 2024: $738 · 2025: $672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,284.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $825.86 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $471.81 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $282.82 | 2019-2025 | |
| Abbvie INC. | $269.36 | 2022-2025 | |
| Lilly USA, LLC | $247.35 | 2019-2024 | Mounjaro, Jardiance |
| Amgen INC. | $177.49 | 2022-2025 | Prolia, Evenity, Repatha |
| Glaxosmithkline, LLC. | $165.19 | 2019-2025 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $135.63 | 2022-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $126.37 | 2022-2024 | Eliquis, Camzyos |
| Sanofi-Aventis U.S. LLC | $118.77 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $96.29 | 2019-2025 | Capvaxive |
| Novartis Pharmaceuticals Corporation | $89.79 | 2022-2024 | |
| Xeris Pharmaceuticals, INC. | $82.33 | 2025 | Recorlev |
| Phathom Pharmaceuticals, INC. | $70.82 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $68.19 | 2023-2024 | Cologuard Collection Kit |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $66.75 | 2019-2022 | |
| Almatica Pharma LLC | $50.35 | 2022-2023 | Gralise, Sertraline Hcl, Loreev Xr |
| Otsuka America Pharmaceutical, INC. | $41.53 | 2023-2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $36.54 | 2022 | |
| Abbott Laboratories | $22.09 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.06 | 2022 | |
| Dexcom, INC. | $20.82 | 2024 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $19.12 | 2024 | Nexletol |
| Lifescan, INC. | $17.50 | 2023 | |
| Axsome Therapeutics, INC. | $15.95 | 2025 | Auvelity |
| Genentech USA, INC. | $15.45 | 2019 | |
| Aytu Biopharma, INC. | $13.84 | 2019 | |
| Amarin Pharma, INC. | $13.74 | 2020 | |
| Aimmune Therapeutics, INC. | $13.50 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $12.80 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.88 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Gutierrez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.